These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32708205)

  • 21. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammatory markers in paroxysmal atrial fibrillation and the protective role of renin-angiotensin-aldosterone system inhibitors.
    Roşianu ŞH; Roşianu AN; Aldica M; Căpâlneanu R; Buzoianu AD
    Clujul Med; 2013; 86(3):217-21. PubMed ID: 26527951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approaches to blockade of the renin-angiotensin-aldosterone system: overview of regulation of the renin-angiotensin-aldosterone system.
    Nishiyama A; Kim-Mitsuyama S
    J Pharmacol Sci; 2010; 113(4):289-91. PubMed ID: 20675960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition.
    Ames MK; Atkins CE; Lantis AC; zum Brunnen J
    J Renin Angiotensin Aldosterone Syst; 2016; 17(1):1470320316633897. PubMed ID: 27009288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renin-Angiotensin-Aldosterone Inhibitors and COVID-19.
    Benenson I; Waldron FA
    J Nurse Pract; 2020; 16(7):545-546. PubMed ID: 32834792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic Changes in the Renin-Angiotensin-Aldosterone System and the Beneficial Effects of Renin-Angiotensin-Aldosterone Inhibitors on Spatial Learning and Memory in a Rat Model of Chronic Cerebral Ischemia.
    Huang X; Lu G; Li G; Li H; Li B; Yin J; Cao S
    Front Neurosci; 2017; 11():359. PubMed ID: 28690496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the Backbenchers of the Renin-Angiotensin System ACE2 and AT2 Receptors in COVID-19: Lessons From SARS.
    Gumashta J; Gumashta R
    Cureus; 2020 Jun; 12(6):e8411. PubMed ID: 32626626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the trend in community prescribing of RAAS inhibitors during the COVID-19 pandemic.
    Guscoth L; Hodgson S
    Br J Cardiol; 2021; 28(4):44. PubMed ID: 35747072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Centrality of G6PD in COVID-19: The Biochemical Rationale and Clinical Implications.
    Buinitskaya Y; Gurinovich R; Wlodaver CG; Kastsiuchenka S
    Front Med (Lausanne); 2020; 7():584112. PubMed ID: 33195336
    [No Abstract]   [Full Text] [Related]  

  • 31. The age again in the eye of the COVID-19 storm: evidence-based decision making.
    Martín MC; Jurado A; Abad-Molina C; Orduña A; Yarce O; Navas AM; Cunill V; Escobar D; Boix F; Burillo-Sanz S; Vegas-Sánchez MC; Jiménez-de Las Pozas Y; Melero J; Aguilar M; Sobieschi OI; López-Hoyos M; Ocejo-Vinyals G; San Segundo D; Almeida D; Medina S; Fernández L; Vergara E; Quirant B; Martínez-Cáceres E; Boiges M; Alonso M; Esparcia-Pinedo L; López-Sanz C; Muñoz-Vico J; López-Palmero S; Trujillo A; Álvarez P; Prada Á; Monzón D; Ontañón J; Marco FM; Mora S; Rojo R; González-Martínez G; Martínez-Saavedra MT; Gil-Herrera J; Cantenys-Molina S; Hernández M; Perurena-Prieto J; Rodríguez-Bayona B; Martínez A; Ocaña E; Molina J
    Immun Ageing; 2021 May; 18(1):24. PubMed ID: 34016150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unquantifiably low aldosterone concentrations are prevalent in hospitalised COVID-19 patients but may not be revealed by chemiluminescent immunoassay.
    Wiegand M; Halsall DJ; Cowan SL; Taylor K; Goudie RJB; Preller J; Gurnell M
    Endocr Connect; 2022 Nov; 11(11):. PubMed ID: 36006845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study.
    Zhang B; Yu Y; Hubert SM; Zhang Y; Lu J; Liu S; Xie F; Zhao L; Lei X; Deng W; Chen J; Li Y
    Front Pharmacol; 2020; 11():576994. PubMed ID: 33192519
    [No Abstract]   [Full Text] [Related]  

  • 34. The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients.
    Vicenzi M; Ruscica M; Iodice S; Rota I; Ratti A; Di Cosola R; Corsini A; Bollati V; Aliberti S; Blasi F
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32933039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenetic Association Underlying Severe COVID-19.
    McCoy K; Peterson A; Tian Y; Sang Y
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33233531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary Exploration of the Cause of Liver Disorders During Early Stages in COVID-19 Patients.
    Gao Y; Li Q; Shi H; Feng Y; Zhang T; Chen Y; Liang L; Chen D; Wu H; Jin R; Huang X
    Front Med (Lausanne); 2020; 7():501. PubMed ID: 32903864
    [No Abstract]   [Full Text] [Related]  

  • 37. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.
    Katsiki N; Banach M; Mikhailidis DP
    Arch Med Sci; 2020; 16(3):485-489. PubMed ID: 32399093
    [No Abstract]   [Full Text] [Related]  

  • 38. Correction to: Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
    Hypertension; 2020 Nov; 76(5):e39. PubMed ID: 33026909
    [No Abstract]   [Full Text] [Related]  

  • 39. Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19.
    Feyaerts D; Hédou J; Gillard J; Chen H; Tsai ES; Peterson LS; Ando K; Manohar M; Do E; Dhondalay GKR; Fitzpatrick J; Artandi M; Chang I; Snow TT; Chinthrajah RS; Warren CM; Wittman R; Meyerowitz JG; Ganio EA; Stelzer IA; Han X; Verdonk F; Gaudillière DK; Mukherjee N; Tsai AS; Rumer KK; Jiang S; Valdés Ferrer SI; Kelly JD; Furman D; Aghaeepour N; Angst MS; Boyd SD; Pinsky BA; Nolan GP; Nadeau KC; Gaudillière B; McIlwain DR
    bioRxiv; 2021 Feb; ():. PubMed ID: 33594362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel pulmonary vascular imaging signs in COVID-19: pathophysiology, significance and management.
    Parry AH; Wani AH
    BJR Open; 2021; 2(1):20210001. PubMed ID: 34381939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.